Based on our success and the bystander effect in hemophilia with an engineered TCR recognizing FVIII, we hypothesized that transduction of an MBP-specific TCR into expanded human Tregs might be an effective therapy in MS. This evidence concerns the gene MBP and myeloid sarcoma.